Bearing in mind that not all proprietary medicines are marketed in all Member States, that the same p
roprietary medicine may be sold with different packaging or content in different Member States, that in some Member States proprietary medicines may be sold only under a brand name rather than their generic name, and that medicines mentioned in a prescription may be in a language unfamiliar to the doctor or pharmacist providing the healthcare, what is the Commission's view as to whether a product prescribed in a prescription, but not marketed in a given Member State, can be replaced by another medicinal product (princeps or generic), bear
...[+++]ing in mind that this practice is outlawed in some Member States?